KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Investments (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Long-Term Investments for 16 consecutive years, with $22.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments fell 67.68% year-over-year to $22.2 million, compared with a TTM value of $22.2 million through Dec 2025, down 67.68%, and an annual FY2025 reading of $22.2 million, down 67.68% over the prior year.
  • Long-Term Investments was $22.2 million for Q4 2025 at Alnylam Pharmaceuticals, down from $51.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $68.6 million in Q4 2024 and bottomed at $22.2 million in Q4 2025.
  • Average Long-Term Investments over 5 years is $49.8 million, with a median of $49.4 million recorded in 2022.
  • The sharpest move saw Long-Term Investments soared 65.38% in 2021, then plummeted 67.68% in 2025.
  • Year by year, Long-Term Investments stood at $40.9 million in 2021, then rose by 20.78% to $49.4 million in 2022, then rose by 0.0% to $49.4 million in 2023, then surged by 38.88% to $68.6 million in 2024, then tumbled by 67.68% to $22.2 million in 2025.
  • Business Quant data shows Long-Term Investments for ALNY at $22.2 million in Q4 2025, $51.3 million in Q3 2025, and $68.6 million in Q2 2025.